SARA GARMON: Open Payments
NPI 1336801406 · SANTA FE, NM. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,494 in 144 payments from 38 companies in 2025. Trend: 2023 $2,936 · 2024 $3,279 · 2025 $3,494
Food & beverage: $2,596Long term medical supply or device loan: $798Education: $100
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 32 | $1,201 |
| AstraZeneca Pharmaceuticals LP | 11 | $196 |
| Janssen Biotech, Inc. | 9 | $183 |
| SOBI, INC | 4 | $175 |
| Celgene Corporation | 16 | $167 |
| Exelixis Inc. | 7 | $151 |
| ABBVIE INC. | 5 | $139 |
| Incyte Corporation | 4 | $92 |
| E.R. Squibb & Sons, L.L.C. | 5 | $85 |
| Merck Sharp & Dohme LLC | 4 | $80 |
Products named: KISQALI, CABOMETYX, REBLOZYL, PLUVICTO, ENHERTU, VENCLEXTA, KEYTRUDA, FRUZAQLA.
Industry payments across NM — which companies pay providers there.
